A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. TKM-PLK-1 targets a protein called polo-like kinase 1 (PLK1) that promotes tumor cell reproduction. It prevents the tumor from completing cell division, resulting in death of the cancer cell. TCRS, a partnership of the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare, will be among the first in the world to study the treatment in humans. The new drug is being developed as a treatment for patients with advanced solid tumor cancers who are not well served by current therapy. The Phase 1 clinical trial will evaluate the safety, tolerability and how the body metabolizes TKM-PLK1.
Clinical trials of TKM-PLK1 for qualified patients are now open at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare, part of the Virginia G. Piper Cancer Center. Researchers hope to enroll up to 52 patients in clinical trials of the drug in three centers across the U.S. Tekmira Pharmaceuticals Corp. of Vancouver, Canada, (http://www.tekmirapharm.com) developed the drug.